GO
Loading...

Enter multiple symbols separated by commas

Stocks Vertex Pharmaceuticals Inc

More

  • FDA approves new Vertex drug, stock halted Thursday, 2 Jul 2015 | 4:20 PM ET
    Vertex Pharmaceutical pill to treat Cystic Fibrosis.

    The FDA approved the use of Vertex Pharmaceuticals' Orkambi, a drug aimed to treat patients with cystic fibrosis.

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks ended little changed as investors eyed the jobs report and were on edge ahead of Greece's Sunday referendum.

  • July 2- Vertex Pharmaceuticals Inc's unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company's reach to the most common form of genetic mutation responsible for cystic fibrosis. Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for...

  • July 2- Vertex Pharmaceuticals Inc's combination therapy for a rare lung disorder was approved by U.S. health regulators, extending the company's reach to now treat the most common form of genetic mutation responsible for cystic fibrosis. Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for patients...

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • 10 drugs to hit fed budget by $50B over decade Tuesday, 9 Jun 2015 | 1:42 PM ET
    Health Care

    Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.

  • Here's how to play weak Q2 earnings season Monday, 18 May 2015 | 7:39 AM ET
    Delta Airlines planes sit at Terminal 4 at John F. Kennedy Airport in New York.

    Negative revenue growth will continue to dog investors in Q2 and Q3, analyst Mike Thompson says. Here's what to do about it.

  • Early movers: DAL, PLL, HUM, VZ, KMB, FB & more Wednesday, 13 May 2015 | 7:56 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • After-hours buzz: American Express, Vertex & more Tuesday, 12 May 2015 | 5:15 PM ET
    Trader on the floor of the New York Stock Exchange.

    Take a look at some of Tuesday's after-hours buzz: American Express, Vertex & more

  • These biotech names are ripe for mergers: Analysts Sunday, 10 May 2015 | 11:00 AM ET
    Biotech pharmaceuticals

    The next takeout target in biotech? Here are three eligible candidates

  • *FDA slated to make decision on treatment on July 5. FDA questioned whether Vertex Pharmaceuticals Inc's experimental combination therapy for cystic fibrosis had an added benefit over the company's already approved therapy, Kalydeco, in patients with the most common genetic mutation behind the deadly disease. The FDA is slated to make a decision on Orkambi...

  • May 8- Vertex Pharmaceuticals Inc's combination of an experimental compound and an approved drug significantyly improved lung function in cystic fibrosis patients with the most common genetic mutation underlying the disease, FDA staff said. The FDA is trying to ask the panel if the evidence is enough to show that the combination's benefit is significantly...

  • May 8- FDA staff reviewers questioned whether Vertex Pharmaceuticals Inc's experimental cystic fibrosis drug added any benefit over its already approved therapy, Kalydeco, in patients with the most common genetic mutation underlying the disease. Vertex is seeking approval for the combination of the compound lumacafotor and Kalydeco to treat CF patients...

  • May 4- Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop...

  • Goldman's top picks Tuesday, 7 Apr 2015 | 2:11 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Brian Sullivan and Dom Chu will list the top 40 cheapest stock picks from Goldman Sachs.

  • Obama seeks $215 million for 'precision medicine' Friday, 30 Jan 2015 | 6:00 AM ET
    President Barack Obama delivers the State of the Union address on January 20, 2015 in the House Chamber of the U.S. Capitol in Washington.

    President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.

  • Drugmakers get mysterious invites to White House Wednesday, 28 Jan 2015 | 5:06 PM ET
    President Barack Obama

    The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • Midday movers: Target, JetBlue, Qualcomm & more Wednesday, 19 Nov 2014 | 1:09 PM ET
    NYSE New York Stock Exchange traders markets

    Some of Wednesday's midday movers: